AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05528939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control video game
Description: The active control program, used in previous studies of this intervention, was designed to match EndeavorRx on expectancy, engagement, and time on task in the form of a challenging and engaging digital word game, targeting cognitive domains not targeted by EndeavorRx and not primarily associated with attentional difficulties. Users are instructed to find and connect letters on a grid to spell words; points are awarded based on number of words formed, word length, and the use of unusual letters. There is progression in difficulty to maintain engagement and expectation of benefit from patients and their caregivers.
Study NCT06096207 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic SenSight Directional DBS lead
Description: At the ninth month post DBS implantation, the participant will enter a discontinuation phase of a duration of 6 weeks. The device will be turned on and off without participants' knowledge. After 6 weeks, the device will be turned back on if it was off. Whether the stimulation is active or not, it will be double blinded.
Study NCT06143878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study NCT06143878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study NCT06143878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113
Description: JNJ-77242113 will be administered orally.
Study NCT06143878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: JNJ-77242113 Matching Placebo
Description: JNJ-77242113 matching placebo will be administered orally.
Study NCT06143878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: JNJ-77242113 Matching Placebo
Description: JNJ-77242113 matching placebo will be administered orally.
Study NCT06143878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Deucravacitinib
Description: Deucravacitinib will be administered orally.
Study NCT06143878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib Matching Placebo
Description: Deucravacitinib matching placebo will be administered orally.
Study NCT06143878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Deucravacitinib Matching Placebo
Description: Deucravacitinib matching placebo will be administered orally.
Study NCT05242484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Guselkumab
Description: Guselkumab will be administered as subcutaneous injection.
Study NCT05242484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Golimumab
Description: Golimumab will be administered as subcutaneous injection.
Study NCT05242484 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-78934804
Description: JNJ-78934804 will be administered subcutaneously as per defined regimen.
Study NCT05242484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as subcutaneous injection.
Study NCT06278363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sexual Nursing care
Description: The Sexual Nursing Care approach is a specialized intervention for stroke patients and partners, addressing sexual health needs. It includes personalized counseling sessions with trained nurses, assessing dysfunctions and medical history. Active partner involvement fosters intimacy and understanding. Both receive sexual education covering anatomy, physiology, and post-stroke changes. Recommendations for activities like Kegel exercises are provided. Structured outpatient sessions occur, lasting 45 minutes, facilitated by a nurse. Pre- and post-treatment assessments are conducted to identify contraindications. Emerging issues during treatment are promptly communicated for management. Sexual Nursing Care aims to holistically address post-stroke sexual health and relational needs, improving awareness and communication.~Coaching and Counselling can be provided also via telemedicine.
Study NCT06278363 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Nursing Care
Description: Group 2 patients receive standard nursing care without structured interventions for sexual dysfunctions. Management relies on clinical case and routine care procedures. No specific sexual sphere interventions are provided. Any emerging issues needing diagnostic investigation are reported to the specialist. Both groups are assessed quantitatively for counseling effects on sexual and relational aspects and qualitatively for psychorelational changes and mood impact on couple's quality of life.
Study NCT04864340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CE marked medical device
Description: Tetanic stimulation
Study NCT04864340 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Algometer
Description: Pressure stimulation
Study NCT04864340 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Comparator
Description: Non-nociceptive procedure (fine touch)
Study NCT03979742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood Mononuclear Cell
Description: Active ingredients: Monocytes, CD34+, CD133+ cells Dose: 4 injections of 16-μliter (100,000 cells/μliter)
Study NCT03979742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Locomotor Training
Description: Locomotor training for up to 6 hours a day, 6 days a week, and for 3-6 months
Study NCT05351229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: 5 mcg/kg intrathecal preservative free morphine sulfate
Study NCT05351229 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline, placebo
Study NCT04842513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multipeptide plus XS15
Description: The vaccine will be applied by subcutaneous injection into the abdominal skin of the study patient. Vaccination will take place monthly (V1, V2 and V3). A total of three vaccinations will be performed. Peptide vaccines should be injected into the skin at the lower part of the abdomen of the patients. The exact site of vaccination (right or left) will be determined at the time of first vaccination and should not be changed during subsequent vaccinations.
Study NCT06385080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered subcutaneously.
Study NCT06385080 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously.
Study NCT06385080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously.
Study NCT06308575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivoceranib
Description: Given by PO
Study NCT05660434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aroma Inhaler with Bergamot essential oil
Description: The intervention group will receive an aroma inhaler and logbook to use three times a day for 7 days and complete pre and post surveys for comfort, ease, and stress.
Study NCT04649385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BGB-15025
Description: Administered orally once or twice daily (QD or BID)
Study NCT04649385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered 200 mg intravenous (IV) infusion
Study NCT04585893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 administered via IV infusion weekly for four weeks. Administered via slow IV infusion, starting at 50mg/hr and increasing by 50mg/hr every 30 minutes to a maximum infusion rate of 400mg/hr.
Study NCT04585893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Subjects with high-risk disease will receive 100 mg/m\^2 etoposide weekly for four weeks administered over one hour via IV infusion after completion of rituximab
Study NCT06249347 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PROMISED
Description: CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Roof linear ablation: linear ablation in the left atria roof; Anterior septal linear ablation: linear ablation in the anterior septal linear which coursed from the middle of the right superior and inferior pulmonary veins or the middle of the right superior pulmonary vein to the mitral valve annulus; Mitral isthmus linear ablation: linear ablation in the mitral isthmus; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.
Study NCT06249347 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CPVI and LAAC
Description: CPVI: Achievement of a wide disconnection of the right and left pulmonary veins; Left atrial appendage closure: Occlusion of the left atrial appendage with a left atrial appendage occlusion device.
Study NCT06249347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation catheter
Description: Device： Radiofrequency ablation catheter
Study NCT06249347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation catheter
Description: Device： Radiofrequency ablation catheter
Study NCT06249347 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: left atrial appendage occlusion device
Description: Device： left atrial appendage occlusion device
Study NCT06249347 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left atrial appendage occlusion device
Description: Device： left atrial appendage occlusion device
Study NCT05529875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: intravenous propofol using target-controlled infusion (TCI) devices.
Study NCT05529875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sevoflurane
Description: inhalator sevoflurane using sevoflurane vaporizer sevoflurane vaporizer.
Study NCT06407557 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Accelerometer
Description: Use of prompts to enable activity in older adults.
Study NCT04488354 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CLBR001 and SWI019
Description: No study drug is administered in this study. Patients who have received CLBR001 autologous CAR-T cells will be evaluated in this trial for long-term safety and efficacy
Study NCT05771896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Darolutamide
Description: Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (>56 days between cycles). Any participant requiring dose interruption >28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly.
Study NCT05771896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: Participants will continue treatment with darolutamide until radiological progression, withdrawal, death, termination, or study completion.~The maximum time for darolutamide dose interruption period is 28 consecutive days beyond scheduled dose (>56 days between cycles). Any participant requiring dose interruption >28 consecutive days beyond the scheduled dose may restart treatment with darolutamide if clinical benefit is anticipated and after discussion with and approval from the study Medical Monitor.~Until primary endpoint is reached, participants are not allowed to switch ARPI (Abiraterone, Apalutamide or Enzalutamide) during the study. Switching to other ARPI following radiographic progression should be considered a subsequent life prolonging therapy and documented accordingly.
Study NCT05771896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radium-223
Description: Radium-223 should be given for 6 cycles, administered IV on Day 1 of each cycle or until radiological progression, withdrawal, death, termination, or study completion. The placebo will be administered in precisely the same fashion as the active drug.~Subsequent cycles 2-6 should be scheduled to occur every 28 ± 7 days following the previous cycle, but dosing may be delayed up to 28 days per cycle (maximum 56 days between cycles). Any participant requiring dose interruption >28 consecutive days (>56 days between cycles) may restart treatment with radium-223/placebo if clinical benefit is anticipated and after discussion with the Medical Monitor. Participants will continue with darolutamide irrespective of Radium-223 administration.~Upon radiological progression, further treatments are decided by the site investigator according to standard local practice.
Study NCT06541028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid-Start ART (RS-ART)
Description: ART initiation within 7 days of HIV diagnosis. (RS-ART intervention to be informed and developed in Aims 1 and 2.) RS-ART is a strategy that focuses on clinical decision-making generally based solely on clinical criteria, and later organizing support for mental health, adherence, and management of comorbid conditions only after the patient has initiated ART.
Study NCT05519683 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEA
Description: The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
Study NCT05519683 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TEA
Description: The TEA device administers a mild electrical shock through the skin, similar to acupuncture. Location sets are described in the protocol, which will be shared with results reporting but are not provided here to maintain masking and, therefore, to safeguard scientific integrity.
Study NCT05519683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lexapro
Description: This arm will receive treatment with the chemical neuromodulator escitalopram (Lexapro) at 10 mg once per day for 8 weeks. Lexapro is often used as a standard treatment for IBS.
Study NCT04699916 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG based protocol for deep sedation
Description: Protocol established to guide sedation drug dosification to maintain the patient with a Suppression Rate (SR) less than 1% and a Spectral Edge Frequency 95 over 10 Hz
Study NCT06656754 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isometric Reaching
Description: The intervention of Isometric Reaching is the process of restricting the participant's hand movement in place, while using the forces they apply to the robot handle to drive a reaching arm simulation
Study NCT06664021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab combined with S-1
Description: Tislelizumab：200mg q3w iv , lasts for one year. S-1：40mg, 50mg, or 60mg orally twice daily for 4 weeks, depending on body surface area, followed by 2 weeks of rest，lasts four cycles.
Study NCT06663319 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-89402638
Description: JNJ-89402638 will be administered.
Study NCT06607341 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-level, community-digital health promotion intervention
Description: Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building
Study NCT06607341 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multi-level, community-digital health promotion intervention
Description: Community level activities:~1. Capacity building for community-based organizations, and~2. Community health workers will facilitate linkage to community resources, including health/social service access referrals and client social support.~Individual level activities:~1. Goal setting and self-monitoring,~2. Tailored feedback,~3. Personalized lifestyle coaching, health and social service referral support, and~4. Digital access and digital health literacy skills building~Social network:~1. Social network-based activities, and~2. Digital health literacy skills building
Study NCT06600412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R3R01
Description: R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.
Study NCT06600412 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Please refer to arm/group description for further information.
Study NCT06589765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-7535 tablet
Description: HRS-7535 tablet
Study NCT06589765 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dapagliflozin tablet
Description: dapagliflozin tablet
Study NCT06590077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aromatherapy
Description: The test intervention is an aromatherapy cosmetic product containing a blend of 5 essential oils (orange, lavender, frankincense, vetiver, and neroli), diluted in apricot kernel oil. It was formulated by a clinical aromatherapist. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
Study NCT06590077 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control (placebo) group
Description: Juniper essential oil in apricot kernel oil in low concentration with a faint aroma - presentation as a rollerball. Each participant will be asked to use the product every evening over 4 weeks and to complete a validated questionnaire at 3 time points: at the beginning, midway after 2 weeks and at the end of the 4-week study.
Study NCT06611228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidomain Interventions
Description: Multidomain Interventions The intervention group will receive a personalized MDI approach from a multidisciplinary team, including a digital coach, physiotherapist, clinical nutrition expert, neuropsychologist, geriatrician, and nurse. This approach will encompass physical activity program, nutritional interventions, cognitive training and stimulation, medication reconciliation, coaching on the use of technological supports, and group activities. Environmental modifications at home will also be proposed
Study NCT06086613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGA2115
Description: In Part A, participants will receive AGA2115 as a single dose administered as a subcutaneous (SC) injection (5 cohorts) or as an intravenous (IV) infusion (1 cohort).~In Part B, participants will receive AGA2115 in multiple doses administered as a SC injection.
Study NCT06086613 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In Part A, participants will receive single dose of placebo administered as a SC injection (5 cohorts) or IV infusion (1 cohort).~In Part B, participants will receive multiple doses of placebo administered as a SC injection.
Study NCT06612125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: volume controlled ventilation
Description: Pediatric patients in the VCV group (n= 30) received volume-controlled ventilation, target tidal volume was set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
Study NCT06612125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled ventilation
Description: Pediatric patients in the PCV group(n=30) received pressure-controlled ventilation. The initial parameters will be as follows: the peak inspiratory pressure (PIP) will set to provide a tidal volume of 7 ml/kg , respiratory rate will be 16 breaths/min, inspiratory to expiratory ratio was 1:2 with an upper limit of PIP of 20 cm H2O.
Study NCT06612125 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pressure controlled volume grantanteed ventilation
Description: Pediatric patients in the PCV-VG group (n=30)will be conducted with pressure-controlled volume-guaranteed ventilation, target tidal volume will set at 7 mL/kg, with a respiratory rate of 16 breaths/min and a respiratory ratio of 1:2.
Study NCT06518057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo CSF sample collection
Study NCT06518057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT
Study NCT06518057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies
Study NCT06518057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture
Study NCT06518057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06518057 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT